Current Clinical Experience with Nevirapine for HIV Infection

  • Andrew Carr
  • David A. Cooper
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 394)


Nevirapine is a non-nucleoside reverse transcriptase inhibitor specific for HIV-1.1,2 This review will focus on some clinically important aspects of the pharmacology and virology of nevirapine, as well as adverse events and the results of some completed clinical studies.


Human ImmunodefiCIency VIruS Human Immunodeficiency Virus Type Human ImmunodefiCIency VIruS Infection Human ImmunodefiCIency VIruS Disease Human Immunodefiency Virus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Merluzzi VJ. Hargrave KD, Labadia M. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 1990;. 250; 1411–3.Google Scholar
  2. 2.
    Koup RA, Merluzzi VJ, Hargrave KD, et al. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587. J Infect Dis 1991; 163: 966–70.PubMedCrossRefGoogle Scholar
  3. 3.
    Nevirapine Investigator’s Brochure. Boerhinger-Ingelheim Pharmaceuticals Inc. 1994.Google Scholar
  4. 4.
    Richman D, Shill CK, Lowy I, et al. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci USA 1991, 88: 11241–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Mellors JW, Dutschman GE, Im GJ, et al. In vitro selection and molecular characterisation of human immunodeficiency virus-1 resistant to nonnucleoside inhibitors of reverse transcriptase. Mol Pharmacol 1992; 41: 446–51.PubMedGoogle Scholar
  6. 6.
    Nunberg J14, Schleif WA, Boots EJ, et al. Viral resistance to human immunodeficiency virus type-lspecific pyridinone reverse transcriptase inhibitors. J Virol 1991; 65: 4887–92.PubMedGoogle Scholar
  7. 7.
    Richman D, Rosenthal AS, Skoog M, et al. BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob Agents Chemother 1991, 35; 305–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Richman DD, Havlir D, Corbeil. Nevirapine resistance mutations of human immunodeficiency virus (HIV) type 1 selected during therapy. J Virol 1994; 68: 1660–6.PubMedGoogle Scholar
  9. 9.
    Cheeseman SH. Havlir D. McLaughlin MM, et al. Phase I/1I evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immun Defic Syndrom Related Retrovir 1995; 8: 141–51.Google Scholar
  10. 10.
    Havlir D, Cheeseman SH, McLaughlin M, et al. High-dose nevirapine: safety, pharmacokinetics and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995; 171: 537–45.PubMedCrossRefGoogle Scholar
  11. 11.
    Larder BA. 3’-azido-3’-deoxythymidine resistance suppressed by a mutation conferring human immunodefiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 1992; 36: 2664–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Richman DD. Nevirapine resistance during clinical trials (abstract). In: Abstracts of the Second International Workshop on HIV Drug Resistance; Noordwijk, June 1993: 26.Google Scholar
  13. 13.
    Carr A Vasak E, Munro V, Penny R, Cooper DA. Immunohistological assessment of cutaneous drug hypersensitivity in patients with HIV infection. Clin Exp Immunol 1994; 97: 250–3.Google Scholar
  14. 14.
    de Jong MD, Loewenthal M, Boucher CAB, et al. Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity. J Infect Dis 1994; 169: 1346–50.PubMedCrossRefGoogle Scholar
  15. 15.
    de Jong M, and the Dutch-Italian-Australian Nevirapine Study Group. Antiviral response to nevirapine monotherapy in nucleoside naive persons. In: Abstracts of the 10th International Conference on AIDS, Yokohama, Japan, August, 1994; Abstract PB0847.Google Scholar
  16. 16.
    Can A, and the Australian-Italian-Dutch Nevirapine Study Group. Efficacy of nevirapinn added to zidovudine in p24-positive HIV-1-infected patients with CD4+ counts less than 500/nun. In: Abstracts of the 10th International Conference on AIDS, Yokohama, Japan, August, 1994; Abstract 511B.Google Scholar
  17. 17.
    Fischi MA. Efficacy and toxicities of combination antiretroviral therapies. In: Program of the 2nd International Congress on Drug Therapy of HIV Infection, Glasgow, United Kingdom, November, 1994: Abstract 7. 2.Google Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Andrew Carr
  • David A. Cooper

There are no affiliations available

Personalised recommendations